A Phase IV Study of Rebif ® 44mcg Administered Three Times Per Week by Subcutaneous Injection Compared With no Treatment in the Therapy of Relapsing Multiple Sclerosis After Mitoxantrone
Clinical trial NCT01142466 · COMPLETED
Trial details
- NCT number
- NCT01142466
- Sponsor
- Merck KGaA, Darmstadt, Germany
- Status
- COMPLETED
- Phase
- Phase 4
- Study type
- INTERVENTIONAL
- Start date
- 2005-12-01
- Primary completion
- 2009-12-01
- Enrollment
- 30
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.